HDAC inhibitors as a potential therapy for chemotherapy-induced neuropathic pain.

Cancer, a chronic disease characterized by uncontrolled cell development, kills millions of people globally. The WHO reported over 10 million cancer deaths in 2020. Anticancer medications destroy healthy and malignant cells. Cancer treatment induces neuropathy. Anticancer drugs cause harm to spinal cord, brain, and peripheral nerve somatosensory neurons, causing chemotherapy-induced neuropathic pain. The chemotherapy-induced mechanisms underlying neuropathic pain are not fully understood. However, neuroinflammation has been identified as one of the various pathways associated with the onset of chemotherapy-induced neuropathic pain. The neuroinflammatory processes may exhibit varying characteristics based on the specific type of anticancer treatment delivered. Neuroinflammatory characteristics have been observed in the spinal cord, where microglia and astrocytes have a significant impact on the development of chemotherapy-induced peripheral neuropathy. The patient's quality of life might be affected by sensory deprivation, loss of consciousness, paralysis, and severe disability. High cancer rates and ineffective treatments are associated with this disease. Recently, histone deacetylases have become a novel treatment target for chemotherapy-induced neuropathic pain. Chemotherapy-induced neuropathic pain may be treated with histone deacetylase inhibitors. Histone deacetylase inhibitors may be a promising therapeutic treatment for chemotherapy-induced neuropathic pain. Common chemotherapeutic drugs, mechanisms, therapeutic treatments for neuropathic pain, and histone deacetylase and its inhibitors in chemotherapy-induced neuropathic pain are covered in this paper. We propose that histone deacetylase inhibitors may treat several aspects of chemotherapy-induced neuropathic pain, and identifying these inhibitors as potentially unique treatments is crucial to the development of various chemotherapeutic combination treatments.

Antinociceptive effect of isoorientin against neuropathic pain induced by the chronic constriction injury of the sciatic nerve in mice.

Neuropathic pain is a widespread and debilitating chronic pain and the treatment remains a clinical challenge. Isoorientin (3',4',5,7-tetrahydroxy-6-C-glucopyranosyl flavone) is a natural flavonoid-like compound that exhibits antioxidant and anti-inflammatory activities; however, its effect on neuropathic pain remains unclear. Our study aimed to evaluate the antinociceptive effect of isoorientin in neuropathic pain mouse models induced by chronic constriction injury (CCI). In our study, the mice with CCI were administered with 7.5, 15, and, 30 mg/kg isoorientin for 8 consecutive days. Behavioral parameters were assayed on days 0, 7, 8, 10, 12, and 14 post-CCI surgery. Electrophysiological, histopathological, and biochemical indices were analyzed on day 14. Immunofluorescence was utilized to examine matrix metalloproteinase-9 (MMP-9) and glial cell activation, and proinflammatory cytokine expression levels were detected via Western blot. It is obvious that the treatment of Isoorientin remarkably ameliorated hyperalgesia and allodynia, increased sensory nerve conduction velocities, and restored CCI-induced sciatic nerve damage in mice. Isoorientin treatment significantly increased the total antioxidant capacity (T-AOC), total superoxide dismutase (T-SOD) and catalase (CAT) levels, and decreased the malondialdehyde (MDA) concentrations. Isoorientin also suppressed MMP-9 and glial cell activation, and downregulated tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-1ß (IL-1ß) expression levels. Therefore, this study provided a novel approach for neuropathic pain treatment and new insights into the pharmacological action of isoorientin.